RxDoctor Payments Data

Alon Davis, MD

Family Medicine · North Miami Beach, FLNPI 1962499657

Payments from drug & device makers

$6,429in general payments, 2019–2025

Across 357 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$715
  • AbbVie$602
  • Novo Nordisk$515
  • GSK$500
  • AstraZeneca$463
  • Amgen$366
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$6,23897%
  • Education$100%
  • Other$1813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,429 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$13,530
Medicare patients
56
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$79,897
TrulicityDulaglutide20$32,790
EliquisApixaban19$24,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$24,148
RybelsusSemaglutide14$20,337
OzempicSemaglutide14$16,843
FarxigaDapagliflozin Propanediol13$9,501
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,357
Atorvastatin Calcium180$2,451
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med13$1,567
Olmesartan Medoxomil33$1,235
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$1,197
Ezetimibe12$1,122
Tamsulosin Hcl51$996
Duloxetine Hcl26$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$221$79,89771 claims
Novo NordiskRybelsus, Ozempic$515$37,18028 claims
Lilly USA, LLCTrulicity$715$32,79020 claims
PfizerEliquis$279$24,75919 claims
GSKTrelegy Ellipta$500$24,14825 claims
AstraZenecaFarxiga$463$9,50113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →